The goal of the Boston Children's Hospital CHRCDA Program is to develop pediatrician physician-scientists who are performing world-class research that will improve health care for children in this country and around the world. Our Scholars will be performing laboratory-based basic and translational research under the mentorship of outstanding scientists at Children's Hospital and other Harvard Associated Hospitals and Harvard Medical School. Our program has been established to ensure the development of independent scientists. In this proposal we describe a program that includes intensive mentoring, a comprehensive didactic program, and a program to ensure the scientific development of Scholars. Programmatic oversight will be provided by an External Site Visit Committee and an Internal Steering Committee. Plans are in place for programmatic self-evaluation and for review of Scholar Progress. We propose to continue the funding of three Scholar positions. Scholars will be funded for a minimum of two years, with further funding contingent on progress and the overall pool of Scholar candidates. Scholars will be faculty members most often at the rank of Instructor, but Assistant Professors who are early in the development of their independent careers will also be eligible to apply. Scholars will be considered at any point from the beginning of their Instructorship to the point where they are considered to be two years away from submitting their first R-level NIH grant or equivalent, though no more than four years beyond the end of fellowship training. Scholars will work in a broad range of scientific investigations. Past and present Scholars have worked in areas such as the mechanism of nuclear reprogramming, structural biology of malaria antigens, immune response to tumors, cancer therapeutics, molecular bases for immunodeficiency, host-microbiome interactions, lung and intestinal stem cells, molecular pathology of streptococcal infection, and disorders of sexual differentiation. These investigations will elucidate fundamental molecular mechanisms and will lead to the development of new therapeutic modalities in all areas of pediatric disease, including hematology/oncology, endocrinology, nephrology, infectious disease, immunology, pulmonology and neurology. !

Public Health Relevance

The Department of Medicine at Boston Children's Hospital is dedicated to the training of physician-scientists and in helping them to develop careers as world- class independent scientists. We have a strong history of producing physician- scientists who have contributed to major discoveries in fundamental basic research and translational research that have had lasting impact on the treatment of pediatric disease. The Child Health Research Career Development Awards have played an integral role in supporting the development of physician-scientists at our institution and we propose to continue and strengthen this program over the next five years.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12HD052896-14
Application #
10072063
Study Section
Special Emphasis Panel (ZHD1)
Program Officer
Winer, Karen
Project Start
2007-03-01
Project End
2022-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
14
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Boston Children's Hospital
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Richmond, Camilla A; Rickner, Hannah; Shah, Manasvi S et al. (2018) JAK/STAT-1 Signaling Is Required for Reserve Intestinal Stem Cell Activation during Intestinal Regeneration Following Acute Inflammation. Stem Cell Reports 10:17-26
Arachchi, Harindra; Wojcik, Monica H; Weisburd, Benjamin et al. (2018) matchbox: An open-source tool for patient matching via the Matchmaker Exchange. Hum Mutat 39:1827-1834
Platt, Craig D; Massaad, Michel J; Cangemi, Brittney et al. (2017) Janus kinase 3 deficiency caused by a homozygous synonymous exonic mutation that creates a dominant splice site. J Allergy Clin Immunol 140:268-271.e6
Pikman, Yana; Alexe, Gabriela; Roti, Giovanni et al. (2017) Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res 23:1012-1024
Daly, Kevin P; Stack, Maria; Eisenga, Michele F et al. (2017) Vascular endothelial growth factor A is associated with the subsequent development of moderate or severe cardiac allograft vasculopathy in pediatric heart transplant recipients. J Heart Lung Transplant 36:434-442
Platt, Craig D; Fried, Ari J; Hoyos-Bachiloglu, Rodrigo et al. (2017) Combined immunodeficiency with EBV positive B cell lymphoma and epidermodysplasia verruciformis due to a novel homozygous mutation in RASGRP1. Clin Immunol 183:142-144
Wassner, Ari J; Jugo, Rebecca H; Dorfman, David M et al. (2017) Myocardial Induction of Type 3 Deiodinase in Dilated Cardiomyopathy. Thyroid 27:732-737
Fenouille, Nina; Bassil, Christopher F; Ben-Sahra, Issam et al. (2017) The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nat Med 23:301-313
Ariyachet, Chaiyaboot; Tovaglieri, Alessio; Xiang, Guanjue et al. (2016) Reprogrammed Stomach Tissue as a Renewable Source of Functional ? Cells for Blood Glucose Regulation. Cell Stem Cell 18:410-21
Rakoff-Nahoum, Seth; Foster, Kevin R; Comstock, Laurie E (2016) The evolution of cooperation within the gut microbiota. Nature 533:255-9

Showing the most recent 10 out of 51 publications